At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved (development code: LY3437943) |
| Targets | GLP-1R + GIPR + GCGR (triple agonist) |
| Developer | Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Phase 3 (TRIUMPH program) |
| Key efficacy | 24.2% weight loss at 24 weeks (12mg, Phase 2) |
| Indications | Obesity, T2D, MASH |
User Sentiment
Retatrutide has no prescription community yet — all data is from Phase 2 trial participants. But the Phase 2 numbers (24.2% weight loss) generated more patient and media discussion than any GLP-1 drug since tirzepatide's first results. The conversation has shifted from "can drugs approach surgery" to "can drugs match surgery."
Example(What Phase 2 participants report)
TRIUMPH Phase 2 participants at 12mg reported appetite suppression described as more complete than tirzepatide — not just reduced hunger, but near-absence of appetite at higher doses. The combination of three receptor mechanisms appears to stack effects in a way trial participants describe as qualitatively different, not just quantitatively more. Weight loss at 24 weeks was still ongoing — the curve hadn't plateaued.
How it works
A single synthetic peptide engineered to activate GLP-1R, GIPR, and GCGR simultaneously with distinct potency ratios: GLP-1R (moderate), GIPR (high), GCGR (moderate). Not a conjugate — the multi-receptor binding is built into the peptide's amino acid sequence.
The three mechanisms operate in parallel:
GLP-1R — appetite suppression through hypothalamic and brainstem signaling; glucose-dependent insulin secretion; gastric emptying delay.
GIPR — synergistic amplification of the GLP-1 appetite signal; enhanced fat mobilization from adipose tissue; effects on energy sensing that GLP-1 alone doesn't fully engage.
GCGR — increased resting energy expenditure (the mechanism absent from single and GLP-1/GIP dual agonists); hepatic fat oxidation; additional CNS appetite effects. Theoretically addresses the metabolic rate adaptation to caloric restriction — the body's tendency to reduce energy expenditure as it loses mass.
Intuition(What 24.2% actually means)
Before GLP-1 drugs, the best pharmacological intervention for obesity produced 5–8% weight loss. Semaglutide at 14.9% was called revolutionary. Tirzepatide at 20.9% extended that ceiling. Retatrutide at 24.2% — at 24 weeks, before the weight loss curve fully plateaus — is now approaching the lower end of what bariatric surgery produces (~25–30% for sleeve gastrectomy). The conversation is no longer about whether drugs can approach surgical outcomes. It's about whether they can match them.
Trial data
Phase 2 TRIUMPH-1 (obesity, 24 weeks):
| Dose | Weight loss |
|---|---|
| 1mg | 7.9% |
| 4mg | 17.3% |
| 8mg | 22.8% |
| 12mg | 24.2% |
24.2% mean weight loss is the highest ever recorded in a Phase 2 obesity trial for any non-surgical intervention. ~100% of participants at 12mg lost at least 5%; ~83% lost at least 15%.
Phase 2 T2D: ~2.0% HbA1c reduction at 12mg alongside substantial weight loss.
Phase 2 MASH: Significant hepatic fat reduction consistent with glucagon agonism mechanism.
What to Expect
Based on Phase 2 TRIUMPH data:
Weeks 1–4 — Slower titration than tirzepatide. The glucagon component requires careful escalation. GI side effects during this phase.
Month 2–4 — Appetite suppression stronger than single or dual-agonist reports at comparable dose stages.
Month 6 — Phase 2 showed 24.2% average at this mark. Individual variation is wide — some participants lost significantly more.
Ongoing — Weight loss was still accumulating at 24 weeks in Phase 2. Phase 3 will give the 72-week picture.
Not available for prescription — Phase 3 TRIUMPH is ongoing. FDA filing expected ~2027.
Dosing and administration
Once-weekly subcutaneous injection. Titration starting at 2mg with escalation every 4 weeks toward 8mg or 12mg maintenance. Slower titration than tirzepatide due to glucagon component requiring careful glucose management during dose escalation.
Development status
| Milestone | Status |
|---|---|
| Phase 2 obesity | Complete — 24.2% at 24 weeks |
| Phase 2 T2D | Complete |
| Phase 2 MASH | Complete |
| Phase 3 TRIUMPH (obesity) | Enrolling — results expected 2026–2027 [verify] |
| Phase 3 T2D | Enrolling |
| FDA filing | ~2027 estimated |
Safety profile
Phase 2 tolerability broadly consistent with GLP-1 class: nausea and vomiting most common during titration, self-resolving in most participants. Heart rate increase observed (class effect). Glucagon component raises theoretical hyperglycemia concern in non-diabetic patients — manageable at Phase 2 dose range through slow titration. No new safety signals specific to the triple mechanism identified in Phase 2. Phase 3 will be the definitive tolerability read at longer duration and larger scale.
Who It's For
- BMI ≥ 30 or ≥ 27 with weight-related conditions — standard obesity drug eligibility
- People who've tried tirzepatide and want to understand what's next
- MASH patients — retatrutide's glucagon component produces liver-specific benefit on top of weight loss
This is the drug to watch in the pipeline. If Phase 3 confirms Phase 2, it becomes the new efficacy standard.
Summary(The retatrutide picture)
24.2% weight loss in Phase 2 — the highest number ever recorded for a non-surgical obesity intervention. Phase 3 TRIUMPH is the definitive test. If confirmed at 22–24%, retatrutide becomes the new efficacy benchmark that the next generation has to beat, and the ceiling question shifts from "can drugs approach surgery" to "can anything do better than three receptors."